Immune cell 'Bridge' offers new hope for tough leukemia
NCT ID NCT07591649
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new immune cell treatment called AdaptNK for people with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. The treatment uses specially selected natural killer cells from a donor, given after chemotherapy, to help control the disease before a stem cell transplant. The goal is to find a safe dose and see if it can lead to remission. About 18 adults aged 18 and older with specific genetic types are being enrolled.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOGENOUS LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mark Juckett, MD
RECRUITINGMinneapolis, Minnesota, 55455, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Personalized leukemia vaccine aims to outsmart relapse
- New transplant recipe aims to tame Graft-Versus-Host disease
- New drug targets genetic weakness in Hard-to-Treat blood cancers
- Cord blood transplant offers hope for young blood cancer patients
- New pill aims to keep leukemia away after transplant
- Experimental drug gentulizumab tested for tough blood cancers – but trial halted early